Biomerica’s Innovative At-Home PSA Test
- Quick 10-Minute Test for Prostate Cancer Detection
- Initial Orders Shipped to Market
- Addressing a Major Health Concern for Men
Biomerica, Inc. (NASDAQ: BMRA), located in Irvine, California, has reached an important milestone with the approval of its Fortel Prostate (PSA) Screening Test by the Saudi Food and Drug Authority (SFDA). This groundbreaking at-home testing solution allows men to swiftly detect early signs of prostate cancer, making vital health monitoring more accessible.
The Fortel Prostate (PSA) Screening Test is a user-friendly rapid diagnostic tool that requires just a simple finger-prick blood sample to assess elevated PSA levels, which can signal prostate health issues, including cancer. With results available in only 10 minutes, this test is designed to promote proactive health screening.
Strategic Growth in the Middle East
This recent approval is a significant step in Biomerica’s plan to enhance its presence in the Middle East, where there is an increasing recognition of the importance of prostate cancer awareness and early detection. By forming partnerships with leading distributors and obtaining essential regulatory approvals, Biomerica is positioning itself as a key player in the region’s healthcare sector. The company has already secured reimbursement for its EZ Detect Colon Disease at-home Screening Test from the Dubai government and aims to achieve similar success with the Fortel PSA test.
Reliable Testing Performance
The Fortel PSA test has demonstrated impressive results in clinical studies. It boasts 100% sensitivity and 95% specificity, achieving an accuracy rate of 97.5% when compared to traditional laboratory methods. A separate study conducted by the Faculty of Medicine at Ain Shams University in Egypt confirmed these results, showing 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy.
Addressing a Growing Global Health Concern
Prostate cancer is a significant global health challenge, with around 1.4 million new cases diagnosed each year, resulting in approximately 375,000 deaths annually. As the second most prevalent cancer among men worldwide, the need for early detection is critical. This urgency is increasingly recognized in the Middle East, where awareness of prostate cancer is rising, although comprehensive research in the region remains scarce.
Future Initiatives
Biomerica has recently sent its first shipment of the Fortel PSA Screening Tests to distributors in Saudi Arabia. The company’s dedication to providing accessible and innovative diagnostic solutions is evident as it seeks to meet the region's pressing demand for early cancer detection methods.
About Biomerica
Biomerica, Inc. (NASDAQ: BMRA) specializes in the development, patenting, and marketing of advanced diagnostic and therapeutic products intended for use at home, in medical offices, and in clinical laboratories. By concentrating on gastrointestinal and inflammatory diseases, Biomerica strives to improve community health while lowering overall healthcare costs.
Frequently Asked Questions
What is the Fortel PSA Screening Test?
The Fortel PSA Screening Test is an at-home test designed to identify elevated prostate-specific antigen (PSA) levels, which can indicate potential prostate health issues.
How does the test work?
This test utilizes a simple finger-prick blood sample and delivers results in just 10 minutes, making it a quick and convenient option for users.
Why is early detection of prostate cancer important?
Detecting prostate cancer early can significantly enhance treatment outcomes and survival rates, making such tests vital for men's health.
Where is the test available?
Currently approved for use in Saudi Arabia, Biomerica is working to broaden the availability of its PSA Screening Test throughout the Middle East.
What other products does Biomerica offer?
In addition to the Fortel PSA Screening Test, Biomerica provides a range of advanced diagnostic and therapeutic products focused on gastrointestinal and inflammatory diseases.
